ClinicalTrials.gg
RecruitingNCT05222828MEPI-AVCUpdated Jan 26, 2024

Effects of Mepivacaine on the Neurological Sequelae of Cerebral Infarction

A Phase 2 interventional study of Carbocaine Injectable Product in Ischemic Stroke, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 4 of them phase 3. Ischemic Stroke · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
14th of 14
38 · median 487
Started
2022
with 2 others
Phase 2
Only one
of the 20
Primary completion
2024-06
later than 1 of 10 live
Registered
9th of 20
by date

Among the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 9th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Ischemic Stroke by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI.

The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, the investigator team will observe a favorable response to subcutaneous mepivacaine injection.

Read the detailed description

A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI. The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, investigator team will observe a favorable response to subcutaneous mepivacaine injection.

The team will include patients with clinically significant sequelae of ischemic stroke, as was the case with the initial patient. In addition,

  • The team hypothesizes that the mechanism of action is not specific to the visual cortex, and therefore should not be limited to visual scotomas
  • It is also preferable to consider only deficits that can be objectively quantified in a sufficiently reliable way to be able to evaluate the effect of the treatment

The investigator teamwill therefore include patients with sequelae of at least one of the following three types:

  • motor deficit: score =\< 56 on the Fugl-Meyer scale, minimal deficit allowing to observe an improvement of 4 points
  • aphasia: score >= 4 on the Aphasia Rapid Test (ART) , minimal deficit allowing to observe an improvement of 4 points
  • visual scotoma: observable on a clinical assessment of the visual field "on confrontation"

Only patients more than 30 days after the occurrence of the stroke will be included. Indeed, the rapid recovery phase after a stroke lasts about 3 weeks and it is difficult to interpret rapid clinical changes and to attribute them to the treatment (since investigator team do not know the time of onset of the effect of mepivacaine) over this temporal period.

Mepivacaine will be administered as a single injection, subcutaneously, at a dose of 3 mL of mepivacaine hydrochloride (20 mg/mL), or 60mg. If mepivacaine is effective, research participants will experience a temporary reduction in neurological symptoms.

Time course of experiment

  1. Signing of consent
  2. Verification of inclusion and exclusion criteria (1h)

    • ECG for all patients
    • Urine dipstick if female of childbearing age
    • Motor, language and visual field scales, depending on the deficit(s) present
  3. Blood sampling
  4. Evaluation of the neurological deficit before treatment (1h)

    • VAS to evaluate the intensity of symptoms by the patient
    • NIHSS
  5. MRI n°1 (duration 45 min to 1h)
  6. Administration of mepivacaine 7 Evaluation of the neurological deficit after treatment, at T= 1+/- 30 minutes after administration (duration 1h)

    • Motor, language and visual field scales, depending on the deficit(s) present
    • VAS to evaluate the intensity of the symptoms by the patient
    • NIHSS

8/ MRI n°2 (duration 30 to 45min) 1h30 after administration 9/ Evaluation of the neurological deficit after treatment, at T= 3h45+/- 45 minutes after administration (duration 1h)

  • Motor, language and visual field scales, depending on the deficit(s) present
  • VAS to evaluate the intensity of the symptoms by the patient
  • NIHSS 9/ Call of the patient 1 week later for follow-up of SAEs and evaluation of the duration of the effect, if any ; if the effect persists, the investigator will call the patient every 2 weeks until returning to the usual state..

Brain imaging

MRI will be performed on a SIEMENS 3 Tesla machine, without injection of contrast medium. The duration of the MRI will be approximately 45 minutes to one hour for MRI n°1 (baseline) and 30 to 45 minutes for MRI n°2 performed after the injection of mepivacaine.

MRI acquisitions will include the following sequences:

  • T1 (only during MRI n°1 in baseline)
  • FLAIR (only during baseline MRI n°1)
  • Diffusion sequence (multishell, multiband)
  • Perfusion sequence (Arterial Spin Labelling, ASL)
  • Resting state BOLD sequence

Drug treatment :

Mepivacaine will be administered:

  • Subcutaneously
  • In the shoulder on the non-dominant side, or on the non-deficient side in case of hemiplegia
  • Dose: 3 mL of mepivacaine hydrochloride (20 mg/mL), or 60mg
  • With at disposal

    • Resuscitation equipment (in particular, a source of oxygen)
    • lipid emulsion to be administered in case of intoxication with clinical signs of neurotoxicity or cardiotoxicity

Genetic samples :

The gene coding for brain-derived neurotrophic factor (BDNF) is of particular interest. BDNF is a protein that contributes to neurogenesis and neuronal differentiation, participates in the creation of new synapses and influences the survival of existing neurons. It is thus currently considered as a crucial element influencing brain plasticity . This could also be an explanatory factor in identifying responders to mepivacaine.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ischemic stroke more than 30 days old
  • Age between 18 and 85 years old
  • At least one deficit among:
  • motor deficit: score \< 56 on the Fugl-Meyer scale
  • aphasia: score ≥4 on the Aphasia Rapid Test,
  • presence of a clinically observable visual scotoma
  • Having given their written consent
  • Be affiliated with a social security scheme, Universal Medical Coverage (CMU) or any equivalent scheme

Exclusion criteria

Exclusion Criteria:

  • to amide-bonded local anesthetics.
  • Atrioventricular conduction disorders requiring permanent electro-systolic training not yet performed.
  • Epilepsy not controlled by treatment.
  • Porphyritic subjects.
  • Patients with a motor deficit (but no aphasia or scotomas) in whom there is spasticity leading to a major reduction in joint amplitude in passive motion
  • Minor patients, under curatorship or guardianship, under legal protection, deprived of liberty, pregnant or breastfeeding women
  • Pathologies involving the vital prognosis or compromising follow-up during the study period
  • Patient undergoing local amine anesthesia in the 7 days preceding V1.
  • Patients currently treated with no anti-arrhythmics such as tocainide, aprindine and mexiletine
  • Patients with a to MRI (ferro-magnetic surgical clips, eye implants, metallic foreign body intraocular or in the nervous system, implants or metallic objects likely to contain the radiofrequency field, cochlear implants, cerebral or cardiac pacemaker , implantable cardiac defibrillators)
  • Patients participating in research involving the therapeutic human person who may modify functional recovery (whether by medication or by medical device) or subject to an exclusion period for another research
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Mepivacaine arm

    mepivacaine injection

    Drug: Carbocaine Injectable Product

Interventions

06

What researchers measure

Primary outcomes

  1. improvement of clinical scores

    The response is defined as an improvement 1h (+/- 30min) after injection, compared to the evaluation before mepivacaine injection, on at least one of the clinical scores specific to the symptoms: * language : decrease of at least 4 points on the ART scale (rated from 0 to 26) , or increase of 20% of the number of images correctly named on a standardized battery (DO80, rated from 0 to 80). The rate of 20% corresponds to an effect considered clinically significant, without any "clinically significant minimal change" published to date. * motor skills : increase of at least 4 points on the Fugl-Meyer scale (rated from 0 to 60) corresponding to the "clinically significant minimal change" in the re-education studies * visual field : 20% reduction of a scotoma evaluated in automated static perimetry of Humphrey by the number of deficit areas compared to the total number of areas evaluated (n=43). The rate of 20% corresponds to an effect considered clinically significant

    Time frame: 1 Day

Secondary outcomes

  1. language-related symptoms

    Relative change, in percentage, in the number of correctly named images on a standardized battery (DO80, rated from 0 to 80) between pre- and 1h(+/-30min) post-injection to measure language-related symptoms.

    Time frame: 1 Day

  2. ART scale

    Absolute change, in number of points, on the ART scale (rated from 0 to 26) between before and 1h(+/-30min) after injection to measure language-related symptoms.

    Time frame: 1 Day

  3. spontaneous language test

    Relative change, of he rate from 0 to 10 at the spontaneous language test between before and 1h(+/-30min) after injection to measure language-related symptoms.

    Time frame: 1 Day

  4. Fugl-Meyer scale

    Absolute change, in number of points, on the Fugl-Meyer scale (rated from 0 to 60), between before and 1h(+/-30min) after injection to measure motor symptoms.

    Time frame: 1Day

  5. Timed up and go test

    relative change, on the Timed up and go test (TUG) (rated in seconds), between before and 1h(+/-30min) after injection to measure motor symptoms.

    Time frame: 1Day

  6. 10 metres walking test

    Relative change, on the 10 metres walking test (rated in seconds), between before and 1h(+/-30min) after injection to measure motor symptoms.

    Time frame: 1Day

  7. Perimetry of Humphrey

    Relative evolution of visual symptoms, measured in automated static perimetry of Humphrey (STAT-30, Metrovision) by the number of deficit areas compared to the total number of assessed areas (n=43), between before and 1h (+/-30min) after injection

    Time frame: 1 Day

  8. kinetic perimetry

    Relative evolution of visual symptoms, measured in kinetic perimetry by the surface of isoptera III/4, between before and 1h (+/-30min) after injection.

    Time frame: 1 Day

  9. static perimetry

    Evolution of visual deficit volumes, measured in static perimetry in dB.deg2, between before and 1h (+/-30min) after injection.

    Time frame: 1 Day

  10. NIHSS score changes

    Change in severity of neurological sequelae measured by the relative change in the National Institutes of Health Stroke Scale (NIHSS score) between before and 1h(+/-30min) after injection.

    Time frame: 1 Day

  11. response delay

    Patient Reported Response Start and End Times

    Time frame: 1 Day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 24 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Feb 3, 2022
StartActual
Jun 22, 2022
Primary completionEst.
Jun 22, 2024
CompletionEst.
Jun 22, 2024
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05222828
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Jun 22, 2022
Primary completion
Jun 22, 2024 (estimated)
Completion
Jun 22, 2024 (estimated)
Last update
Jan 26, 2024

Study contacts

COHEN Laurent, PUPH
Contact
laurent.cohen@aphp.fr
142161801 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mepivacaine

Start the discussion